Who makes BMS-986231 Formulation D?

BMS-986231 Formulation D is developed by Bristol-Myers Squibb.

What development phase is BMS-986231 Formulation D in?

BMS-986231 Formulation D is in Phase 1.

Last reviewed 2026-04-19 · How we verify

BMS-986231 Formulation D

Bristol-Myers Squibb · Phase 1 active Small molecule

BMS-986231 Formulation D is an investigational drug by Bristol-Myers Squibb that has completed a Phase 1 study assessing its pharmacokinetics, safety, and tolerability in healthy participants. No FDA label is available, and the drug is not yet approved for any indication.

At a glance

Generic name	BMS-986231 Formulation D
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BMS-986231 Formulation D CI brief — competitive landscape report
BMS-986231 Formulation D updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI